|
Re: ALTTO Trial - Herceptin / Tykerb
The Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation study, or ALTTO, is an international, phase III clinical trial of two targeted therapies for HER2-positive breast cancer. HER2 is a protein found in high levels on up to 25 percent of all breast cancers. Tumors that overproduce HER2 tend to be more aggressive and more likely to recur than those that do not.
|